SS-31 / Elamipretide: Cardiolipin & Mitochondrial Research

Explore the aromatic-cationic peptide, its association with cardiolipin studies, and the distinction between mechanistic data and product-specific clinical outcomes.

A structurally specific peptide

SS-31, also called elamipretide in its development and medicine context, is a synthetic aromatic-cationic tetrapeptide. Its residue modifications and stereochemistry are part of the molecular identity.

It is studied in relation to mitochondrial membranes and cardiolipin, a lipid important to that environment. A specific interaction in this setting is more precise than the broad phrase mitochondrial support.

What the mechanistic paper examined

Birk and colleagues investigated SS-31-associated cardiolipin and cytochrome-c behavior, connecting those observations with mitochondrial bioenergetic measurements. The work addresses a defined mechanistic system. ^[1]

It should not be presented as proving that every person will experience more energy or that aging is reversed. Clinical claims, where applicable, belong to their own identified trials, formulation and indication.

Choose an endpoint that fits the claim

Membrane interactions, oxygen-consumption measurements and ATP-associated endpoints describe related but distinct aspects of mitochondrial behavior. A changed value needs to be interpreted alongside viability, baseline state and the experimental setup.

If a study proposes that cardiolipin-associated behavior explains an outcome, ask whether the necessary mechanistic steps were tested. A plausible explanation can be useful while still requiring additional evidence.

Clinical naming does not establish product equivalence

A molecule's development or medicine history does not make every research sample carrying a similar name equivalent to a regulated formulation. Identity, concentration, excipients and quality controls remain separate issues.

This article introduces the mechanistic literature. It does not provide a personal-use protocol, state a universal regulatory status or claim that an unrelated research preparation reproduces a product-specific clinical result.

Questions to bring to the evidence

• What mitochondrial property did the experiment actually measure?
• Does the evidence concern this exact molecular and formulation identity?

Sources & further reading

1. Birk et al. (2014): SS-31, cardiolipin and mitochondrial functionPrimary mechanistic study